Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) EBIAT (2020 - 2026)

Cytek Biosciences filings provide 6 years of EBIAT readings, the most recent being -$44.1 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 557.08% to -$44.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$66.5 million, a 1005.48% decrease, with the full-year FY2025 number at -$66.5 million, down 1005.3% from a year prior.
  • EBIAT hit -$44.1 million in Q4 2025 for Cytek Biosciences, down from -$5.5 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $9.6 million in Q4 2024 to a low of -$44.1 million in Q4 2025.
  • Median EBIAT over the past 5 years was -$1.7 million (2021), compared with a mean of -$4.0 million.
  • The widest YoY moves for EBIAT: up 419.14% in 2022, down 2215.69% in 2022.
  • Cytek Biosciences' EBIAT stood at -$1.2 million in 2021, then soared by 419.14% to $3.7 million in 2022, then skyrocketed by 48.01% to $5.5 million in 2023, then soared by 75.23% to $9.6 million in 2024, then plummeted by 557.08% to -$44.1 million in 2025.
  • The last three reported values for EBIAT were -$44.1 million (Q4 2025), -$5.5 million (Q3 2025), and -$5.6 million (Q2 2025) per Business Quant data.